title: [Concomitant intraperitoneal therapy with the antitumor polysaccharide Sizofiran and rG-CSF for ovarian cancer].
abstract: The concomitant administration of Sizofiran (a macrophage activator) and rG-CSF (which promotes neutrophil proliferation and activation) caused marked activation of intraperitoneal antitumor immunity. It promoted the induction of IL-2 receptor expression as well as the proliferation and activation of neutrophils, and also caused an increase in LAK and NK activity, which resulted in a clinical antitumor effect. Therefore, this concomitant regimen was found to be useful as maintenance therapy for ovarian cancer.
authors.affiliation: Dept. of Obstetrics and Gynecology, Tokyo Medical College.
authors.forename: T
authors.initials: T
authors.lastname: Hoshino
authors.forename: Y
authors.initials: Y
authors.lastname: Suzuki
authors.forename: M
authors.initials: M
authors.lastname: Takeichi
authors.forename: T
authors.initials: T
authors.lastname: Adachi
authors.forename: M
authors.initials: M
authors.lastname: Yagishita
authors.forename: M
authors.initials: M
authors.lastname: Takayama
mesh_terms: D004334:Drug Administration Schedule; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D007263:Infusions, Parenteral; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology; D010051:Ovarian Neoplasms / Q000276:immunology / Q000628:therapy*; D015375:Receptors, Interleukin-2 / Q000276:immunology; D012566:Sizofiran / Q000008:administration & dosage*
chemical_list: D015375:Receptors, Interleukin-2; D016179:Granulocyte Colony-Stimulating Factor; D012566:Sizofiran